NCT00093600View on ClinicalTrials.gov

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

midostaurin

Trial Locations (6)

77030

MD Anderson Cancer Center/University of Texas, Houston

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

02115

Dana Faber Cancer Institute, Boston

48201-2014

Wayne State University/Karmanos Cancer Institute, Detroit

Unknown

Novartis Investigative Site, Dresden

Novartis Investigative Site, Mainz

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY